[Polish Gynecological Society's recommendations regarding ovarian cancer].
Explore the source record for details and available documents.
Female↗
Biomedical subjects
Stanisław Radowicki
Publications and source records attributed to Stanisław Radowicki.
[Effectiveness and safety of the treatment of menopausal syndrome with Cimicifuga racemosa dry extract].
OBJECTIVES: Phytoestrogens could be an alternative method of the treatment of menopausal syndrome in women with contraindications to hormonal replacement therapy. DESIGN: The aim of the study was to evaluate efficacy and safety of the therapy with Cimicifuga racemosa dry extract. MATERIAL AND METHODS: Twenty women aged mean 52.4 +/- 4.9 years with climacteric syndrome were treated with Cimicifuga racemosa dry extract in a dose of 40 mg a day during 6 months. Kupperman's Index, biochemical parameters and hormonal profile were estimated before and after 3 and 6 months of the therapy. RESULTS: Mean values of Kuppermen's Index were decreased from 30.2 +/- 5.7 points before the therapy to 8.5 +/- 6.3 points after 3 months and to 2.6 +/- 2.1 points after 6 months of the therapy (p < 0.05). No statistical differences in biochemical parameters' concentrations and hormonal profile were observed. CONCLUSIONS: Cimicifuga racemosa dry extract was an effective and safe therapy of climacteric women with contraindications to hormonal replacement therapy.
Cimicifuga↗
[Recommendations of the Polish Society of Obstetrics and Gynecology for women urinary incontinence]].
Explore the source record for details and available documents.
Female↗
[Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
OBJECTIVE: evaluation of the frequency of adverse events during the therapy with a transdermal contraceptive system (TCS) in comparison to an oral contraceptive. MATERIAL AND METHODS: 20 healthy women aged 23.8 +/- 4.1 years without contraindication to steroid hormonal therapy and a history of dermal hypersensitivity to adhesive applications. All patients were treated with either contraceptive patches containing 20 microg ethinyl estradiol (EE) and 150 microg norelgestromin (17-dNGM) or a monophasic oral contraceptive containing 20 microg EE and 150 microg desogestrel during 6 cycles. Safety evaluation was based on the frequency of adverse effects, changes in physical and gynecological examinations. RESULTS: The incidence of most adverse effects was similar between the transdermal and oral contraceptive therapies, except of a higher incidence of breast pain, dysmenorrhoea and application site reactions in the patch group. 50% of patients demonstrated gastro-intestinal complaints in the oral contraceptive group. None of the patients discontinued the hormonal contraceptive therapies due to adverse effects. CONCLUSION: The study suggests that a transdermal contraceptive system is a safe and well tolerated therapy.
Administration, Cutaneous↗
[Effect and tolerability of sequential administration of estradiol valerate and medroxyprogesterone acetate on menopausal symptoms, hormonal profile and biochemical markers in climacteric women].
UNLABELLED: Hormonal replacement therapy is the gold standard in the treatment and prophylaxis of menopausal symptoms and osteoporosis. THE AIM: Of the study was to assess changes in climacteric symptoms, hormonal profile and biochemical parameters during sequential hormonal replacement therapy in climacteric women 19 women aged 46-61 years old was included into the study. We evaluated Kuppermann's index, serum concentration of estradiol, FSH, morphology of the blood, lipids and haemostatic parameters. RESULTS: The menopausal symptoms significantly decreased. Lipids levels, haemostatic parameters and morphological parameters of the blood didn't change. CONCLUSION: The sequential hormonal replacement therapy with estradiol valerate and medroxy-progesterone acetate is efficient and safe.
Aged↗
[Influence of hormone replacement therapy (oral and transdermal) on activity of erythrocyte Zn/Cu superoxide dismutase (Zn/Cu-SOD) in postmenopausal women].
OBJECTIVE: The aim of the study was to determine the effect of hormone replacement therapy (oral and transdermal) on the erythrocyte antioxidant enzyme activity in postmenopausal women. DESIGN: Prospective clinical study. MATERIAL AND METHODS: The erythrocyte Cu/Zn superoxide dismutase activity was measured in 14 postmenopausal women (the mean age 58.5 +/- 5.1 years) who received either oral (7) or transdermal (7) HRT. Additionally the activity of the enzyme was compared between the subgroup of healthy women and those with coronary heart disease (CHD). The measurements was made by the use of commercial kit (Bioxytech SOD-525 TM Assay). RESULTS: There were no differences statistically significant between erythrocyte Cu/Zn-SOD activity before and after 3 months of HRT in all patients. However, lower activity of erythrocyte Cu/Zn-SOD was observed in the subgroup of women who were suffering from (CHD) in comparison to their healthy volunteers. The way of HRT administration also influenced erythrocyte Cu/Zn-SOD activity. The erythrocyte Cu/Zn-SOD activity after 3 months of treatment was slightly higher in group who received oral HRT. CONCLUSIONS: HRT (oral and transdermal) leads to changes in erythrocyte Cu/Zn-SOD activity. The presence of (CHD) postmenopausal women seems to influence the erythrocyte Cu/Zn-SOD activity.
Administration, Cutaneous↗
[Oral contraceptive practices among female medical students of the University of Warsaw].
DESIGN: Apparently no researches have been conducted regarding oral contraceptive usage among female medical students in Poland. In the last ten years, all over the world, only five publications have dealt with this topic. OBJECTIVES: The purpose of the research reported in this article was to establish the types, choices and frequency of usage of oral contraceptive pills among female medical students of the University of Warsaw. MATERIAL AND METHODS: 634 female students responded to a specially designed questionnaire. RESULTS: Data collected indicated that, 52.2% of the students have been involved in sexual intercourse. 167 of them used Oral Contraceptive Pills (OCP). Two third survey participants used OCP following a doctors recommendations. CONCLUSIONS: 1.30.5% of the sexually active students used OCP. 2.31.9% of this group of students believed the use of OCP was the most effective of all the contraceptive methods. 3.65.0% of the respondents used OCP following a doctors recommendations. 22.7% of the survey participants used OCP in order to regulate their menstrual cycles. 4. The respondents who reported customary use of OCP cited the most frequently used OCP as: Cilest-28.0%, Mercilon-19.2% and Minulet-13.2%.
Adult↗
[Menstrual disturbances and alternations in hypophyseal gonadal axis in end-stage premenopausal women undergoing hemodialysis: a multi-center study].
The results of the studies of hypophyseal-gonadal axis in dialysis women are not uniform. Mostly the increased serum concentrations of prolactine and pituitary gonadotropins are observed; the data about ovarian secretion are much more scanty and contradictory. The aim of this crossectional study was to assess changes in sexual hormones secretion and their associations with menstrual disturbations in premenopausal women with end-stage renal failure undergoing hemodialysis. Sixty three women from six mazovian dialysis units, aged 18-45 years (mean 35 +/- 7 years) were enrolled into the study. They were divided into four groups according to their menstrual pattern: I--eumenorrhoea (n = 17), II--polymenorrhoea (n = 9), III--oligomenorrhoea (n = 16) i IV--amenorrhoea n = 21). There were no differences between both groups in respect to age, age of menarche, time on hemodialysis, and body mass index. In all subjects gynecological examination was performed and serum prolactin, FSH, LH, estradiol, progesterone and testosterone concentrations were assayed. In 49% women high serum prolactin concentrations were noted (the highest in group IV--1699 +/- 1022 vs 441 +/- 205 microIU/ml in group I; p < 0.05). Mean serum FSH and LH were increased in group IV only (33 +/- 59 and 22 +/- 31 mIU/ml); no significant differences among groups examined were seen. Serum estradiol was increased in groups I-III (95 +/- 46, 72 +/- 33, and 83 +/- 55 pg/ml, respectively) and decreased in group IV (27 +/- 22 pg/ml; p < 0.001 in respect to remaining groups). Mean serum progesterone and testosterone concentrations were normal in all four groups, but serum progesterone was significantly lower in groups II-IV than in group I (p < 0.05). No differences in hormonal status between patients receiving and not receiving rHuEpo were observed. Menstrual disturbances are common (73%) in premenopausal women with end-stage renal failure, with amenorrhea constituting a half of them. Hyperprolactinemia is the most frequently seen alteration in their hormonal profile with the highest concentrations in those with secondary amenorrhea. Increased serum gonadotropins and reduced serum estradiol concentrations are mostly seen in amenorrheic women, whereas in menstruating women serum estradiol is often slightly increased.
Adolescent↗
[Contraceptive practices among students].
Research has shown that university students tend to have specific sexual behaviour. It is worth mentioning that not much attention has been paid to pregnancy prevention practices among medical students nor has any survey been conducted in this matter. The purpose of this survey was to ascertain the frequency of contraceptive usage among students at Medical University of Warsaw. Specially designed questionnaires were anonymously self-administered by 634 female and 354 male medical students. 52.2% of the female students and 67.2% of the male students were sexually active at the time. 43.4% of the survey participants used condoms, while 26.3% used oral contraception pill (OCP) as contraceptive methods. Only 0.5% of those participants used intrauterine device. The survey result indicates an apparent dichotomy between the male and female students in terms of (appropriate) choice of the following contraceptive methods: condom, OCP, withdrawal, basal body temperature and Billings' methods.
Adult↗
[Treatment of hyperplasia endometrium with GNRH agonists].
OBJECTIVES: Untreated hormonal disturbances connected with unbalanced estrogen serum concentrations can influence on pathological proliferation of endometrium. The aim of the study is to assess the effect of GnRH agonists on endometrium in women consulted due to simple hyperplasia endometrium. MATERIAL AND METHODS: 15 women in the mean age 48.5 +/- 3.5 years with the histopathological diagnosis of simple hyperplasia were treated with trioptorelin during 3 months. After therapy all patients were undergone transvaginal ultrasonography and endometrial biopsy. RESULTS: Atrophic endometrium were observed in all women after a 3-month therapy. The thickness of endometrium decreased from 10.21 +/- 3.2 mm to 3.94 +/- 1.56 mm. CONCLUSIONS: The efficacy of the therapy of simple hyperplasia in women with GnRH agonist was 100%.
Antineoplastic Agents, Hormonal↗
[Changes in bone density in hemodialysed women treated with transdermal hormone replacement therapy].
OBJECTIVES: Renal insufficiency in women can cause menstrual disturbances and changes of hormonal profile leading to the decrease of bone mass density. Drug administration during dialysis also influences the bone density and increases the risk of osteoporosis. The aim of the study is to assess the effect of transdermal hormonal replacement therapy (HRT) in hemodialysed patients with secondary amenorrhea on bone density. MATERIAL AND METHODS: 10 women aged from 22 to 45 years old were enrolled in the study. They received 17 beta-estradiol and norethisterone acetate in patches during 12 cycles. Densitometer of lumbar spine and serum estradiol concentration were measured before and after 12 cycles of therapy. RESULTS: The recurrence of regular vaginal bleeding, the increase of estradiol levels and bone mass density rate about 6% were observed. CONCLUSIONS: Transdermal hormonal replacement therapy in hemodialysed women with secondary amenorrhea revealed the efficacy of the treatment and prevention from osteoporosis.
Administration, Cutaneous↗
[Influence of a new monophasic oral contraceptive on body metabolism].
OBJECTIVES: Androgenic activity as adverse effects of oral contraception can influence on discontinuation of the therapy. New gestagens used in oral contraception do not reveal androgenic activity. The aim of the study is to assess the safety of the therapy with a new monophasic oral contraception on metabolism. MATERIAL AND METHODS: 99 healthy women aged mean 23.5 +/- 2.1 years were enrolled in the study. They received a monophasic contraceptive pill containing 30 micrograms ethinylestradiol and 2.0 mg dienogest during 13 cycles. Biochemical parameters in blood were measured before and after 6 and 12 cycles of therapy. RESULTS: The concentrations of liver enzymes, glucose and lipids did not differ significantly. CONCLUSIONS: The study suggests that a new monophasic oral contraceptive pill containing 30 micrograms ethinylestradiol and 2.0 mg dienogest is safe and good tolerated preparation.
Adolescent↗
17beta-estradiol regulation of human growth hormone (hGH), insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) axis in hypoestrogenic, hypergonadotropic women.
OBJECTIVE: Ovarian hormonal function may be as important contributing factor to hGH-IGF-I-IGFBP-3 axis as age. AIM: To examine plasma hGH, IGF-1 and IGFBP-3 levels in women with premature ovarian failure compared to healthy normal controls and postmenopausal ones. PATIENTS: Group A-15 women with premature ovarian failure (POF) (mean: age 38.9+/-5.2 years, FSH 101.4+/-29.0 IU/l; 17beta-estradiol 22.5+/-14.6 ng/l). Group B consisted of 15 menopausal women (mean: age 54.7+/-2.7 years; FSH 81.9+/-32.1 IU/l; 17beta-estradiol 17.1+/- 8.0 ng/l). Group C - controls - 15 normally menstruating women (mean: age 37.1+/-9.0 years; FSH 6.2+/-1.0 IU/l; 17beta-estradiol 144.8+/-117.1 ng/l). METHODS: Body mass and BMI were measured. Basic fasting plasma hGH, IGF-I, IGFBP-3, insulin, testosterone and LH as well as prolactin (PRL), FSH and estradiol were assessed by RIA kits. Statistical analysis. Shapiro-Wilk test, Mann-Whitney u-test, Spearman rang correlation coefficient, stepwise multiple regression. RESULTS: Mean serum IGF-I level was the lowest (p<0.005) in group B (172.0+/-54.6 microg/l) and the highest in group C (273.6+/-109.0 microg/l). The mean plasma IGF-I level in group A was similar (NS) (208.3+/-66.5 microg/l) to that found in group B and lower (p<0.02) compared with that in group C. The lowest (p<0.005) serum IGFBP-3 level was found in group B (3.1+/-0.7 microg/l) compared to group C (4.4+/-0.3 microg/l). The mean plasma IGFBP-3 level (3.1+/-1.0 microg/l) in group A was lower than in group C (p<0.005) but identical as in group B. No statistically significant differences between groups were observed in mean hGH levels. Women in group A and C were younger (p<0.001) than those in group B. The lowest mean estradiol level was found in groups A and B. The highest was in group C (p<0.001). Mean plasma LH and FSH levels were higher (p<0.001) in groups A and B vs group C. In group C there were links between IGF-I and age (r=-0.60; p=0.014) The IGF-I/age relation disappeared in the groups A and B (rA=-0.26; rB=0.10; NS). The same regards IGFBP-3/ age link (rA=-0.44, NS; rB=0,31;NS). Estradiol level was related to hGH levels in group C (r=-0.54; p<0.05). In none of groups hGH/IGF-1 as well as IGFBP-3/hGH relations were found. Prolactin accounted for 69% of the variance in IGF-I level in the group B (p=0.003) and for 24% in group A (NS). Testosterone accounted for 88% (p=0.004) of the variance in IGF-I level in group B and IGFBP-3 was responsible for 86% (p=0.038) of the variance in IGF-I level in group C. Again IGFBP-3 was responsible for 47% (p=0.023) in group A and for 49% (p=0.04) in group B of the hGH variance. CONCLUSIONS: 17b-estradiol may be as important contributor to insulin-like growth factor-I (IGF-I) plasma level as age in hypoestrogenic, hypogonadotropic women.
Adult↗